logo
Share SHARE
FONT-SIZE Plus   Neg

Novartis: RLX030 Improved Symptoms, Mortality In Heart Patients

Swiss drugmaker Novartis AG (NVS) Monday said results from a new analysis of the Phase III RELAX-AHF study indicate that the investigational medicine RLX030 or serelaxin consistently improved symptoms and mortality across multiple subgroups of patients with acute heart failure or AHFassessed in the trial.

The results were published today in the European Heart Journal and presented as a late breaker at the European Society of Cardiology congress in Amsterdam.

The addition of RLX030 to conventional treatment led to improvements in breathlessness and mortality at 6 months across all pre-specified subgroups including those with renal impairment, the elderly and patients with atrial fibrillation, although the small numbers of patients in each group limit the statistical conclusions that can be drawn.

Novartis said AHF patients require urgent treatment and that prompt decision-making to stop heart failure worsening is crucial in spite of patients often having diverse clinical profiles.

RLX030 is currently being assessed by health authorities around the world including the US Food and Drug Administration and the European Medicines Agency for the treatment of AHF. In June, the FDA granted RLX030 Breakthrough Therapy designation status, recognizing its potential to address a serious unmet medical need.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Internet access is growing worldwide, but there is still a long way to go before the entire world is completely wired, a study from the Pew Research Center has found. The study also noted that men have greater access to the Internet than women in many nations. Backtracking on its early announcements on digital privacy, WhatsApp is planning to share member information, phone numbers and analytical data with Facebook, to make revenue from the platform. Discount retailers Dollar Tree Inc. and Dollar General Corp. both reported results for the second quarter that missed analysts' expectations. Looking ahead, Dollar Tree also forecast revenue for the third quarter below analysts' estimates and lowered its full-year revenue outlook. Shares of both companies are falling in pre-market activity.
comments powered by Disqus
Follow RTT